Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

Actelion announces commencement of share repurchase program (Actelion Ltd)

$
0
0
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 23 March 2015 - Actelion (SIX: ATLN) announced today that it has received approval from the relevant authorities to launch the repurchase of up to 10 million shares (8.76% of currently issued capital), over three years. The repurchase program will be carried out via a second trading line on the SIX Swiss Exchange established for this purpose (SIX: ATLNE). Trading is expected to commence on 9 April 2015 and will run over a maximum of three years. At subsequent Annual General Meetings, Actelion's Board of Directors will propose that the shares bought through this program be cancelled and the issued share capital reduced accordingly. Jean-Paul...

Viewing all articles
Browse latest Browse all 480

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>